Trial Profile
Efficacy and Safety of Mino-Lok Therapy (MLT) in Combination With Systemic Antibiotics in the Treatment of Catheter-Related or Central Line-Associated Bloodstream Infection
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Jan 2024
Price :
$35
*
At a glance
- Drugs Alcohol/disodium edetate/minocycline (Primary) ; Antibacterials; Heparin
- Indications Catheter infections
- Focus Registrational; Therapeutic Use
- Sponsors Citius Pharmaceuticals Inc; Leonard Meron Biosciences
- 02 Jan 2024 According to a Citius Pharmaceuticals media release, enrollment completed in study at the end of 2023. Topline results are expected in the second quarter of 2024.
- 02 Jan 2024 Status changed from recruiting to active, no longer recruiting, according to a Citius Pharmaceuticals media release.
- 14 Aug 2023 According to a Citius Pharmaceuticals media release, company expecting research and development expenses will stabilize in fiscal 2023 as focus is on the commercialization of LYMPHIR and complete Phase 3 trial for Mino-Lok and Phase 2b trial for Halo-Lido.